Thiram

Thiram

SCHEMBL5078490

CN(C)C(=S)SSC(=S)N(C)C.CSC

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 8/20 0.87
ALDH1A1 P00352 7/20 0.87
ALDH2 P05091 4/20 0.87
LMNA P02545 3/20 0.87
HTT P42858 3/20 0.87
TP53 P04637 3/20 0.87
HPGD P15428 3/20 0.87
ALOX15 P16050 3/20 0.87
ALOX12 P18054 3/20 0.87
HSD17B10 Q99714 3/20 0.87
FAAH O00519 3/20 0.87
HSP90AA1 P07900 2/20 0.87
CYP3A4 P08684 2/20 0.87
FBP1 P09467 2/20 0.87
MAPT P10636 2/20 0.87
PKM P14618 2/20 0.87
LOX P28300 2/20 0.87
LOXL3 P58215 2/20 0.87
KMT2A Q03164 2/20 0.87
NPSR1 Q6W5P4 2/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiram SCHEMBL21144 0.93 ALDH1A1 (1.00) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL1216571 0.93 ALDH1A1 (1.00) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL305889 0.90 ALDH1A1 (0.81) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL3741643 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL10884509 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL23248447 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL2773352 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL10881913 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL10883678 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT
Thiram SCHEMBL234787 0.90 ALDH1A1 (0.93) MGLLALDH1A1ALDH2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4053400-A PRECIPITATION WITH AN ALKYLTHIURAM SULFIDE COMPOUND THE METALUX CORPORATION (US) 1977-10-11 US claimed
US-20230115675-A1 METHODS OF TREATING CANCER BROAD INST INC (US) 2023-04-13 US disclosed
EP-4111202-A1 METHODS OF TREATING CANCER The Broad Institute Inc. (US) 2023-01-04 EP disclosed
US-20190119057-A1 PAPER FEEDING ROLL SUMITOMO RIKO COMPANY LIMITED (JP) 2019-04-25 US disclosed
US-7335707-B2 For pneumatic tire containing 4-phenyl isocyanate and sulfur as crosslinking material, with increased filler/reinforcing material loading; improved green strength, aged flex life, tear, and reversion resistance THE GOODYEAR TIRE & RUBBER COMPANY (US) 2008-02-26 US disclosed
US-20070100030-A1 Barrier layer composition THE GOODYEAR TIRE & RUBBER COMPANY 2007-05-03 US disclosed
EP-0504320-B1 METHOD FOR PREPARING STERICALLY HINDERED ARYL PHOSPHITES UNIROYAL CHEM CO INC (US) 1994-09-21 EP disclosed
US-5254709-A Catalytic reaction of phosphorus trihalide with a phenolic compound UNIROYAL CHEMICAL COMPANY, INC. (US) 1993-10-19 US disclosed
EP-0504320-A1 METHOD FOR PREPARING STERICALLY HINDERED ARYL PHOSPHITES. UNIROYAL CHEM CO INC (US) 1992-09-23 EP disclosed
WO-1991009040-A1 METHOD FOR PREPARING STERICALLY HINDERED ARYL PHOSPHITES UNIROYAL CHEMICAL COMPANY, INC. (US) 1991-06-27 WO disclosed
US-4774288-A PHENOLIC RESIN VULCANIZATION SYSTEM POLYSAR LIMITED (CA) 1988-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115675-A1 METHODS OF TREATING CANCER SOD1, RNASE1, COXFA4L2 MGLL 3712/4885ALDH1A1 727/4885ALDH2 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.